

“No Red Tape, Only Red Carpet”: CM Yogi Adityanath Unveils Uttar Pradesh’s Pharma Growth Vision at Pharma Conclave

Uttar Pradesh Emerges as India’s Next Pharma Powerhouse; ₹10,000 Crore MoUs Signed, 11 Exchanged at the Conclave

From Policy to Production: CM Yogi Adityanath Positions Uttar Pradesh as a Global Pharma Investment Destination

Lucknow, February 3:

Uttar Pradesh took a decisive step towards cementing its position as a leading pharmaceutical and healthcare manufacturing hub with the successful inauguration of the Uttar Pradesh Pharma Conclave by **Hon’ble Chief Minister Shri Yogi Adityanath**. The event was attended by **Hon’ble Deputy Chief Minister Shri Brajesh Pathak**, senior ministers, policymakers, and leaders from the pharmaceutical and medical devices industry.

Welcoming investors and industry representatives, the Chief Minister highlighted Uttar Pradesh’s remarkable transformation into a business-friendly and investment-ready state, reiterating the government’s strong commitment to partnering with global and domestic pharmaceutical players for long-term and sustainable growth.

Addressing the conclave, the Chief Minister said that Uttar Pradesh has decisively moved away from cumbersome procedures to a governance model driven by efficiency and transparency. Summing up this transformation, he remarked, **“There is no red tape in Uttar Pradesh—only a red carpet for investors.”** He underlined the state’s significant improvements in road, rail, air, and digital connectivity, noting that robust infrastructure is now driving industrial expansion across the state.

Highlighting flagship initiatives, the Chief Minister referred to the **Lalitpur Bulk Drug Pharma Park** and the **Medical Device Park near the upcoming international airport** as clear indicators of the state’s intent to build a strong, end-to-end pharmaceutical ecosystem. He emphasized that these projects will strengthen domestic manufacturing, reduce import dependence, and enhance India’s global competitiveness in the pharma sector.

Stressing the importance of research, innovation, and technology in healthcare, the Chief Minister cited premier institutions such as **IIT Kanpur, SGPGI, CDRI, and NBRI** as key pillars supporting advanced R&D and industry–academia collaboration. He also highlighted environmental progress, including increased forest cover, along with progressive sector-specific policies, the **Nivesh Mitra single-window clearance**

system, availability of a vast industrial land bank, plug-and-play facilities, and time-bound incentives for investors.

Reaffirming the state's commitment to zero political interference and a strong law-and-order framework, he noted that these reforms have helped Uttar Pradesh emerge as a top performer in Ease of Doing Business rankings. He also spoke about the rapid growth of MSMEs and the ODOP initiative, rising FDI inflows, forward-looking pharma policies, startup and skill-development programmes, and the increasing adoption of artificial intelligence in healthcare delivery.

A major highlight of the conclave was the signing of **Memorandums of Understanding (MoUs) worth nearly ₹10,000 crore** in the pharmaceutical sector. **Eleven MoUs were exchanged** in the presence of the Chief Minister, reflecting strong investor confidence in Uttar Pradesh. Key investment commitments included **₹1,250 crore each from Arna Pharma and Biogenta Lifesciences Pvt. Ltd., ₹737 crore from Shukra Pharmaceuticals Limited, ₹590 crore from Walter Bushnell Enterprise Pvt. Ltd., and ₹553 crore from Jhanvika Labs Private Limited**, along with additional investments from **Coro Health GCC and Marc Laboratories Limited**. These investments are expected to significantly boost employment, innovation, and healthcare manufacturing in the state.

The conclave also featured a high-level **Round Table Meeting with the Hon'ble Chief Minister**, enabling direct dialogue with senior pharmaceutical industry leaders.

Several interactive and thematic sessions were organised to chart the long-term growth roadmap for the sector. These sessions facilitated meaningful engagement with national pharma associations, manufacturers, and industry partners, while one-on-one meetings enabled focused discussions on policy support, investment facilitation, innovation, and future expansion strategies.

Shri Nand Gopal Gupta "Nandi", Hon'ble Minister for Industrial Development, Export Promotion, NRI and Investment Promotion, Government of Uttar Pradesh, highlighted the state's rapid industrial and economic growth under the guidance of **Hon'ble Prime Minister Shri Narendra Modi** and the leadership of **Hon'ble Chief Minister Shri Yogi Adityanath**. He stated that Uttar Pradesh today offers some of the most competitive policies and incentives in the country, supported by improved law and order, which has significantly strengthened investor confidence. Describing medicines and pharmaceuticals as symbols of hope and trust, he praised doctors as lifesavers and emphasized inclusive, well-planned industrial development backed by effective implementation.

He also highlighted Uttar Pradesh's proactive COVID-19 response, the critical role of drug inspectors, strong investor handholding mechanisms, FDI-friendly policies, focused development of Bundelkhand, and the strategic importance of the **Lalitpur Bulk Drug**

Park. Reaffirming Uttar Pradesh's emergence as a pharma hub, he assured investors of a safe, secure, and supportive investment environment.

At the conclave, **Shri Alok Kumar, Additional Chief Secretary, Industrial Development and MSME, Government of Uttar Pradesh**, welcomed the dignitaries and presented **"Destination Uttar Pradesh."** He highlighted the state's economic strengths, including exports, MSMEs, ODOP, electricity availability, GSDP growth, demographic dividend, land bank, and superior connectivity. He outlined the vision of making Uttar Pradesh a **six-trillion-dollar economy by 2047**, supported by robust infrastructure and business-friendly governance.

Pharma Conclave 1.0 saw participation from senior leadership of some of India's most prominent pharmaceutical companies, including **Padma Shri Dilip Shanghvi**, Chairman of Sun Pharma; **Padma Bhushan Pankaj R. Patel**, Chairman of Zydus Lifesciences; **Shri Ramesh Juneja**, Chairman of Mankind Pharma; **Dr. Satish Reddy**, Chairman of Dr. Reddy's Laboratories; **Shri Jinal Mehta**, Vice Chairman of Torrent Group; and senior representatives from the Ramky Group. These leaders engaged in focused discussions on manufacturing expansion, innovation-led growth, regulatory facilitation, and emerging investment opportunities in Uttar Pradesh, signalling strong industry confidence in the state's pharma potential.

Sessions on **"Competitive Pharma Ecosystem – Infrastructure, Industry and Regulation"** and **"Pharma, Medical Devices and GCC Sector: Research and Innovation"** witnessed active participation from leading industry experts, policymakers, and academic leaders. **Hon'ble Minister of State for Health and Family Welfare Shri Mayankeshwar Sharan Singh** emphasized that Uttar Pradesh has emerged as a catalyst for change, fostering a transformed ecosystem that supports innovation, manufacturing, and investment.

During the interactions, the **CEO of YEIDA** highlighted the availability of industrial land, proximity to the NCR, and excellent connectivity, positioning the region as a preferred destination for pharma investments.

Shri Daya Shankar Mishra 'Dayalu', Hon'ble Minister of Food Safety, Drug Administration, and Ayush Department, also graced the conclave with his presence. Concluding the deliberations, **Dr. G. N. Singh, Advisor to the Hon'ble Chief Minister**, highlighted Uttar Pradesh's vast pharma market potential, progressive policies, and emerging growth opportunities—reaffirming the state's commitment to becoming a global hub for pharmaceutical and healthcare manufacturing.
